Agios Pharmaceuticals
AGIO
156 hedge funds and large institutions have $1.31B invested in Agios Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 61 increasing their positions, 48 reducing their positions, and 20 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 48
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
2.04% less ownership
Funds ownership: 109.62% → 107.58% (-2%)
3% less funds holding
Funds holding: 161 → 156 (-5)
25% less capital invested
Capital invested by funds: $1.74B → $1.31B (-$435M)
47% less call options, than puts
Call options by funds: $4.27M | Put options by funds: $8.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$25.8M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$9.77M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$9.29M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.52M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.5M |
| 2 |
JP Morgan Chase
New York
|
-$42.1M |
| 3 |
CC
Casdin Capital
New York
|
-$29.5M |
| 4 |
BlackRock
New York
|
-$8.22M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.49M |
AGIO Hedge Fund Activity: Q2 2022 in Review
156 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2022, worth a combined $1.31B — down 25% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AGIO and 19 opened new positions — a net loss of 1 holder — while 48 trimmed existing stakes and 61 added.
The largest buyer was Suvretta Capital Management, adding an estimated $25.8M. The largest seller was Fidelity Investments, cutting an estimated $42.5M.
- 156 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2022, down from 161 in Q1 2022.
- Funds reported $1.31B of Agios Pharmaceuticals stock for Q2 2022, down 25% quarter-over-quarter.
- 19 funds opened new Agios Pharmaceuticals positions in Q2 2022 and 20 closed out, a net change of -1 holder.
- The largest Agios Pharmaceuticals buyer in Q2 2022 was Suvretta Capital Management, an estimated $25.8M added.
- The largest Agios Pharmaceuticals seller in Q2 2022 was Fidelity Investments, an estimated $42.5M sold.
Based on aggregated 13F filings for Q2 2022.